Cardiol Therapeutics, Inc. (CRDL)

NASDAQ: CRDL · IEX Real-Time Price · USD
0.982
-0.018 (-1.77%)
At close: Oct 4, 2022 4:00 PM
0.990
+0.008 (0.78%)
After-hours: Oct 4, 2022 6:14 PM EDT
-1.77%
Market Cap 62.73M
Revenue (ttm) n/a
Net Income (ttm) -31.61M
Shares Out 63.86M
EPS (ttm) -0.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 435,386
Open 1.050
Previous Close 1.000
Day's Range 0.935 - 1.050
52-Week Range 0.935 - 4.960
Beta 0.95
Analysts Buy
Price Target 3.64 (+270.6%)
Earnings Date Nov 9, 2022

About CRDL

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of... [Read more...]

Industry Drug Manufacturers-Specialty & Generic
Founded 2017
Employees 2,021
Stock Exchange NASDAQ
Ticker Symbol CRDL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for CRDL stock is "Buy." The 12-month stock price forecast is 3.64, which is an increase of 270.56% from the latest price.

Price Target
$3.64
(270.56% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reve...

Data Presented at The Annual Scientific Meeting of the Heart Failure Society of America September 30th, 2022Oakville, Ontario--(Newsfile Corp. - October 3, 2022) - Cardiol Therapeutics Inc.

1 day ago - Newsfile Corp

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of A...

Oakville, Ontario--(Newsfile Corp. - September 28, 2022) - Cardiol Therapeutics Inc.

6 days ago - Newsfile Corp

Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treat...

Multi-center, international, double-blind, randomized, placebo-controlled trial to enroll 100 patientsOakville, Ontario--(Newsfile Corp. - August 3, 2022) - Cardiol Therapeutics Inc.

2 months ago - Newsfile Corp

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Oakville, Ontario--(Newsfile Corp. - June 29, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research an...

3 months ago - Newsfile Corp

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT

Oakville, Ontario--(Newsfile Corp. - June 27, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research an...

3 months ago - Newsfile Corp

Cardiol Therapeutics Announces At-The-Market Equity Offering Program

Oakville, Ontario--(Newsfile Corp. - June 9, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and...

3 months ago - Newsfile Corp

Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors

Oakville, Ontario--(Newsfile Corp. - May 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and...

4 months ago - Newsfile Corp

Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II ...

Third IND authorization for CardiolRx™ in cardiovascular diseaseStudy to run in parallel with Company's multi-national Phase II acute myocarditis trial, expected to commence imminently CardiolRx™ is now...

4 months ago - Newsfile Corp

Cardiol Therapeutics Announces Year-End 2021 Update on Operations

Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19Received authorization from the FDA to p...

6 months ago - Newsfile Corp

Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit

Oakville, Ontario--(Newsfile Corp. - March 22, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research a...

6 months ago - Newsfile Corp

Cardiol Therapeutics Appoints Jennifer M. Chao to Its Board of Directors

Oakville, Ontario--(Newsfile Corp. - March 15, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research a...

6 months ago - Newsfile Corp

Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Proto...

LANCER Trial expanded to include up to 20 Additional Clinical Research CentersOakville, Ontario--(Newsfile Corp. - March 1, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the...

7 months ago - Newsfile Corp

Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board

Oakville, Ontario--(Newsfile Corp. - January 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research...

8 months ago - Newsfile Corp

Cardiol Therapeutics Announces Closing of US$50 Million Public Offering

Oakville, Ontario--(Newsfile Corp. - November 5, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing a...

10 months ago - Newsfile Corp

CRDL Stock: 7 Things to Know About Healthcare Play Cardiol Therapeutics

Today, CRDL stock is down despite very positive news of a Health Canada approval for a Phase 2 trial of the company's leading drug. The post CRDL Stock: 7 Things to Know About Healthcare Play Cardiol Th...

11 months ago - InvestorPlace

Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

Oakville, Ontario--(Newsfile Corp. - October 25, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing i...

11 months ago - Newsfile Corp

Cardiol Therapeutics Appoints Michael J. Willner to Its Board of Directors

Oakville, Ontario--(Newsfile Corp. - September 7, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing ...

1 year ago - Newsfile Corp

Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial...

Oakville, Ontario--(Newsfile Corp. - August 24, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing in...

1 year ago - Newsfile Corp

Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts Think Are Ready to Pop

As we begin another week, here's a look at some of the best short squeeze stocks available to investors according to research from Fintel. The post Short Squeeze Stocks: VRPX, CRDL and 3 Others Experts ...

Other symbols: NAOVVRPXBTBT
1 year ago - InvestorPlace

Cardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL"

Oakville, Ontario--(Newsfile Corp. - August 9, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-in...

1 year ago - Newsfile Corp

Cardiol Therapeutics' Board of Directors Appoints Dr. Guillermo Torre-Amione as Chairman

Oakville, Ontario--(Newsfile Corp. - July 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on devel...

1 year ago - Newsfile Corp

Cardiol Therapeutics Reports Results of 2021 Annual General and Special Meeting

Oakville, Ontario--(Newsfile Corp. - June 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on deve...

1 year ago - Newsfile Corp

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting on June 29th at 4:30 p.m. EDT

Oakville, Ontario--(Newsfile Corp. - June 28, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on deve...

1 year ago - Newsfile Corp

Cardiol Therapeutics Closes $22 Million Bought Deal Offering

Oakville, Ontario--(Newsfile Corp. - May 12, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-infl...

1 year ago - Newsfile Corp

Cardiol Therapeutics Announces First Patient Enrolled in LANCER, a Phase II/III Outcomes Trial in High-Risk Patients ...

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular diseaseOakville, On...

1 year ago - Newsfile Corp